Ionis-Novartis heart drug misses main goal of late-stage trial

IONS•2026-09-04

Late-stage heart drug trial misses main goal

Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a type of fat and protein particle in heart patients missed the main goal in a late-stage trial, the companies said on Friday.

Ionis-Novartis heart drug misses main goal of late-stage trial

Late-stage heart drug trial misses main goal

Related News

MarketAxess announces special shareholder meeting

FingerMotion prices registered direct offering at $0.24 per share with pre-funded warrants

Star Bulk takes delivery of two Kamsarmax newbuilds for USD 70.2 million cash outlay

AstraZeneca says FDA approves Etcamah-CDK4/6 combo for first-line advanced HR-positive breast cancer

Polar Power announces annual shareholder meeting